Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Nebraska
Scripps Health
Masonic Cancer Center, University of Minnesota
University of Michigan Rogel Cancer Center
Mayo Clinic
GlaxoSmithKline
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
MedImmune LLC